Susquehanna International Group
APRE icon

Susquehanna International Group’s Aprea Therapeutics APRE Stock Holding History

Susquehanna International Group’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-510
Closed -$19K – 12814
2022
Q1 		$19K Sell
510
-1,200
-70% -$49.2K ﹤0.01% 12632
2021
Q4 		$98K Sell
1,710
-4,965
-74% -$439K ﹤0.01% 12166
2021
Q3 		$682K Buy
6,675
+3,115
+88% +$283K ﹤0.01% 8592
2021
Q2 		$347K Buy
3,560
+2,555
+254% +$236K ﹤0.01% 10455
2021
Q1 		$103K Buy
+1,005
New +$117K ﹤0.01% 11847

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's APRE Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Aprea Therapeutics (APRE) in Q1 2026: 13,018 shares worth $9.93K. The stake represents ﹤0.01% of the portfolio and ranks #12940 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in APRE as recently as Q2 2024.

Susquehanna International Group first reported a position in APRE in Q2 2021 and has held it in 9 quarters since. The position peaked at $1.02M in Q3 2021. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • Susquehanna International Group held 13,018 shares of Aprea Therapeutics worth $9.93K as of Q1 2026.
  • Aprea Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Aprea Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12940 holding.
  • Susquehanna International Group first reported a position in Aprea Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Susquehanna International Group's Aprea Therapeutics position peaked at $1.02M in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.